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Summary
Reperfusion hemorrhage is an independent predictor of
adverse left-ventricular remodeling following acute myo-
cardial infarction. Iron chelation may potentially allevi-
ate the toxic and pro-inflammatory effects of iron
degradation products. CMR can provide insights into
the interaction between hemorrhage and iron chelator.
Background
It has been speculated that iron chelation may be bene-
ficial in acute myocardial infarction (AMI) and that
early treatment can limit ischemia-reperfusion injury
and also reduce infarct size. However, the role of iron
chelation in hemorrhagic myocardial infarction, where it
would be most suited, has not yet been explored. Reper-
fusion hemorrhage results in accumulation of iron
degradation products of hemoglobin that may be pro-
inflammatory as free iron is toxic in nature. The pur-
pose of the study was to investigate the interaction
between iron chelating agent deferiprone (DFP) and
hemorrhage in a porcine model of myocardial infarction
and monitor remodeling by cardiovascular magnetic
resonance (CMR).
Methods
The study involved two groups of animals that were
subjected to a 90 min balloon occlusion of the LAD fol-
lowed by reperfusion - untreated (N=2) and DFP treated
(N=2). DFP (supported by ApoPharma Inc., Toronto,
ON) was administered (orally) a few hours before the
procedure (pre-loading) and treatment was continued
with a daily dose of 100 mg/kg. Imaging was performed
on a 3T MRI scanner (MR 750, GE Healthcare) pre-
AMI (healthy) and day 2-week 4 post-AMI. Edema was
evaluated by T2 quantification using a T2-prepared
spiral sequence and hemorrhage was identified by T2*
determined using a multi-echo gradient-echo acquisi-
tion. Infarct assessment was performed by delayed
hyperenhancement (DHE) using an IR-GRE sequence.
Results
Figure 1 demonstrates representative images from the
two groups while Figure 2 shows the cumulative time
course of the CMR measurements. In the DFP group,
hemorrhage was observed only on day 2 and by week 1
it had completely resolved. This was in contrast to the
untreated group where resolution of hemorrhage was
delayed to week 4. With DFP, inflammation or edema
was substantially reduced by week 4 with T2 values
approaching control levels. In the untreated group,
edema persisted up to week 4. Ejection fraction (EF)
was depressed by week 4 in both groups. However, end-
diastolic and end-systolic volumes were relatively
unchanged in the DFP group while they increased sig-
nificantly in the untreated group.
Conclusions
Hemorrhage may be a source of iron toxicity and a
mediator of inflammation, directly contributing to
adverse remodeling in the setting of AMI. DFP was able
to penetrate the infarct zone and was also effective in
neutralizing hemorrhagic byproducts. Elimination of
hemorrhage resulted in faster resolution of edema and
normal ventricular volumes, representing a beneficial
remodeling process. Iron chelation could potentially
serve as an adjunctive therapy in hemorrhagic AMI.
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Figure 1 Short axis images from a representative animals subjected
to 90 min LAD occlusion without (top panel) and with (bottom
panel) treatment of iron chelator deferiprone (DFP). In the DFP
group, hemorrhage, as indicated by T2* image (red arrows) was
observed only on day 2 but resolved by week 1, unlike the
untreated group where hemorrhage persisted even at week 1. The
iron neutralizing capacity of DFP is apparent from this example. In
both groups, microvascular obstruction (MVO) was seen on day 2
that was partially resolved by week 1.
Figure 2 Cumulative time course of T2 and T2* parameters post-
AMI pooled across all animals (N=2) in the 90 min infarct -
untreated (top panel) and treated with deferiprone (DFP, bottom
panel); error bars show standard error and day 0 indicates control
MRI scans in healthy animals. Infarct zone is shown in red; remote
myocardium is shown in blue; hemorrhagic core is shown in black.
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